Article
Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes.
Leukemia - 1 Jul 2015
Pfeifer M, Zheng B, Erdmann T, Koeppen H, McCord R, Grau M, Staiger A, Chai A, Sandmann T, Madle H, Dörken B, Chu Y-W, Chen A I, Lebovic D, Salles G A, Czuczman M S, Palanca-Wessels M C, Press O W, Advani R, Morschhauser F, Cheson B D, Lenz P, Ott G, Polson A G, Mundt K E, Lenz G
Abstract excerpt
Antibody drug conjugates (ADCs), in which cytotoxic drugs are linked to antibodies targeting antigens on tumor cells, represent promising novel agents for the treatment of malignant lymphomas. Pinatuzumab vedotin is an anti-CD22 ADC and polatuzumab vedotin an anti-CD79B ADC that are both linked to the microtubule-disrupting agent monomethyl auristatin E (MMAE). In the present study, we analyzed the activity of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.